With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This class of drugs has fundamentally altered the healthcare sector's growth projections. As the market matures, advisors are increasingly evaluating weight loss ETFs to capture this thematic shift. THNR: The Index-Based Pure Play The Amplify Weight Loss Drug & Treatment ETF (THNR) offers an index-based entry point ...